AQR Capital Management LLC Grows Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

AQR Capital Management LLC lifted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 158.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 48,452 shares of the company’s stock after purchasing an additional 29,727 shares during the period. AQR Capital Management LLC’s holdings in ImmunityBio were worth $306,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Lazard Asset Management LLC lifted its position in shares of ImmunityBio by 102.6% during the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock worth $68,000 after purchasing an additional 6,593 shares during the last quarter. Blair William & Co. IL raised its stake in ImmunityBio by 106.3% during the 1st quarter. Blair William & Co. IL now owns 313,542 shares of the company’s stock worth $1,684,000 after acquiring an additional 161,530 shares in the last quarter. Axxcess Wealth Management LLC acquired a new stake in ImmunityBio during the 1st quarter worth $85,000. Vanguard Group Inc. raised its stake in ImmunityBio by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company’s stock worth $72,708,000 after acquiring an additional 211,065 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in ImmunityBio during the 4th quarter worth $304,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $3.71 on Thursday. The company’s fifty day moving average price is $3.75 and its 200 day moving average price is $5.43. ImmunityBio, Inc. has a 12 month low of $1.25 and a 12 month high of $10.53. The firm has a market capitalization of $2.57 billion, a P/E ratio of -3.40 and a beta of 1.02.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.53 million. On average, sell-side analysts anticipate that ImmunityBio, Inc. will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their price target on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research note on Monday, August 19th.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.